Amid desperate efforts to find a treatment for the neurodegenerative disease Alzheimer’s, the aducanumab saga continues, as a US Food and Drug Administration panel will determine whether a post-hoc ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback